Søren Weis Dahl
Directeur Général chez Deck Therapeutics, Inc.
Postes actifs de Søren Weis Dahl
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Deck Therapeutics, Inc.
 Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020. | Directeur/Membre du Conseil | 01/01/2014 | - |
| Directeur Général | 01/01/2014 | - |
Historique de carrière de Søren Weis Dahl
Anciens postes connus de Søren Weis Dahl
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| PILA PHARMA AB | Directeur/Membre du Conseil | 30/05/2023 | 01/04/2024 |
Prophylix AS
 Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Directeur Général | 01/04/2015 | 01/01/2019 |
Formation de Søren Weis Dahl
| Technical University of Denmark | Graduate Degree |
| Copenhagen Business School | Masters Business Admin |
Statistiques
Internationale
| Danemark | 3 |
| Norvège | 2 |
| Etats-Unis | 2 |
Opérationnelle
| Chief Executive Officer | 2 |
| Director/Board Member | 2 |
| Graduate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PILA PHARMA AB | Health Technology |
| Entreprise privées | 2 |
|---|---|
Prophylix AS
Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Health Technology |
Deck Therapeutics, Inc.
Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020. | Health Technology |
- Bourse
- Insiders
- Søren Weis Dahl
- Expérience
